The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Hepatocellular Carcinoma: An Epidemiologic View
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is estimated to cause approximately half a million deaths annually. Because of its high fatality rates, the incidence and mortality rates are almost equal. The major risk factors for HCC are chronic hepatitis B virus infection, chronic hepatitis C virus (HCV) infection, and alcoholic cirrhosis. The epidemiology of HCC is characterized by marked demographic (age, gender, race/ethnicity) and geographic variations. Hepatitis B virus infection, with and without aflatoxin exposure, is responsible for most cases in developing countries; better control of these risk factors has resulted in a recent decline in HCC in some places like Taiwan and China. Recently, however, a trend of rising rates of HCC has been reported from several developed countries in Europe and North America. These new trends are associated with "new" risk factors such as HCV and, possibly, diabetes. In the United States, the incidence of HCC has approximately doubled over the past 3 decades. White individuals are two to three times less often affected than African Americans, who in turn are two to three times less often affected than Asians, Pacific Islanders, or Native Americans. Men are two to three times more often affected than women. Concomitant with the rising rates of HCC, there has been a shift of incidence from typically elderly patients to relatively younger patients between ages of 40 to 60 years. An increase in HCV-related HCC accounts for at least half of the witnessed increase in HCC in the United States. Hepatocellular carcinoma continues to carry an overall dismal survival rate (close to 5%); very few patients qualify for and receive potentially curative therapy. The future incidence trends of HCC will be determined to a large extent by the clinical course of HCV-infected people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Cited by
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,071
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Venook, A. P., Papandreou, C., Furuse, J., & Ladrón de Guevara, L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-05 · Cited by 965
Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma
Xu, M. Z., Yao, T., Lee, N. P. Y., Ng, I. O. L., Chan, Y., Zender, L., Lowe, S. W., Poon, R. T. P., & Luk, J. M. (2009) · Cancer · doi:10.1002/cncr.24495 · Cited by 528
Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
Chen, X., & Calvisi, D. F. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.12.002 · Cited by 434
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 391
Metadata
- Authors
- El-Serag, H. B.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2002-11
- Volume
- 35
- Issue
- 5 Suppl 2
- Pages
- S72-S78
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2042165138
- Cited by
- 633
- References
- 1
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatocellular Carcinoma: An Epidemiologic View. https://app.cochat.ai/papers/10.1097/00004836-200211002-00002
- The paper
- El-Serag, H. B. (2002). Hepatocellular Carcinoma: An Epidemiologic View. Journal of Clinical Gastroenterology. https://doi.org/10.1097/00004836-200211002-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.